Case Study: Rare disease (PAH) – Patient finding

The Prospection Platform helped a top pharmaceutical company simplify complex brand decision making surrounding Pulmonary Arterial Hypertension (PAH) to support patient programs with the aim to deliver earlier diagnoses and better referral programs. Our analysis identified anomalies across geographies for diagnosis and referrals by specialties. We equipped our client with these on-demand insights that enabled them to determine PAH stakeholders and decide how to achieve earlier diagnosis, better referrals, and improved patient outcomes.
Are high coronary risk patients missing out on lipid-lowering drugs in Australia?
To examine whether high coronary risk patients in Australia, where
use of lipid-lowering drugs (LLD) is very high by international standards, are
receiving LLD.
Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience
To study treatment persistence and mortality using a single-pill, fixed-dose combination
tablet compared with a two-pill combination for hypertension.